Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New oral painkiller KHN702 enters human testing for Post-Op pain

NCT ID NCT07277933

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new oral drug called KHN702 for moderate to severe pain after surgery. About 24 adults will receive either the drug or a placebo to see if it is safe and helps reduce pain. The study is double-blind, meaning neither patients nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KHN702 tablet
What this could lead to
If it works, this could lead to a new oral painkiller for post-surgery pain.
What could go wrong
This is a very early Phase 1 trial with only 24 people. It is designed mainly to check safety, not prove effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects between the ages of 18 and 75 years, inclusive. 2. Body mass index (BMI) of 18.0 to 30.0 kg/m2, inclusive. 3. Patients scheduled for surgery. 4. According to the researcher's medical judgment, American Society of Anesthesiologists (ASA) classification≤Grade II. 5. The subject can understand and comply with the study procedures and requirements, and can provide written informed consent prior to any study procedures. 6. NRS ≥ 4 points within 6 hours after surgery. Exclusion Criteria: 1. Participants experiencing acute or chronic pain unrelated to the surgical site, which the investigator deems may confound the participant's assessment of postoperative pain. 2. History or evidence of any of the following conditions prior to screening: * History of significant cardiovascular or cerebrovascular disease; * Severe respiratory disease history; * Severe Neurological and Psychiatric disease History; * Active peptic ulcer disease, significant vomiting, chronic diarrhea, ileus, malabsorption, or other known conditions that significantly affect drug absorption, distribution, metabolism, or excretion; * Subjects at high risk of bleeding who are deemed unsuitable for this trial by the investigator; 3. Long-term use of opioids or nonsteroidal anti-inflammatory drugs within the past 30 days prior to screening, or discontinuation of medications affecting analgesic efficacy assessment (except those permitted by the protocol) less than 5 half-life prior to randomization. 4. Subjects with a history of opioid allergy, or those with a history of allergy to the intraoperative medications specified in the protocol, postoperative rescue analgesics, or known allergies to the investigational drug or its excipients. 5. Subjects who underwent major surgery within 3 months prior to screening and the investigator determined that it would affect postoperative pain assessment. 6. Any of the following infectious diseases were present during screening: Hepatitis B surface antigen (HBsAg) positive, hepatitis C virus antibody (HCV Ab) positive, human immunodeficiency virus antibody (HIV Ab) positive, or serum treponema pallidum antibody (TPAb) positive. 7. History of substance abuse or alcohol abuse within the three months prior to screening . 8. History of blood donation within the past three months prior to screening. 9. Individuals who have participated in any clinical research within the past three months prior to screening . 10. Pregnant or lactating women; women or men of reproductive potential who are unwilling to use contraception throughout the study period; or subjects (including male subjects) planning to conceive within 3 months after study completion. 11. Subjects with intraoperative blood loss exceeding 1000 mL or those experiencing other severe complications during surgery; 12. Subjects requiring intensive care following surgery; 13. Other circumstances deemed unsuitable for participation in this trial by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postoperative pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.